Italia markets closed

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,1200+0,0800 (+1,98%)
Alla chiusura: 04:00PM EDT
4,2100 +0,09 (+2,18%)
Dopo ore: 07:58PM EDT

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357
https://www.biopathholdings.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno10

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Peter H. Nielsen MBACo-Founder, Chairman of the Board, CEO, President, CFO & Treasurer696,24kN/D1949
Mr. Douglas P. MorrisCo-Founder, Director of Investor Relations, Secretary & Director73,74kN/D1956
Mr. Michael Hickey M.B.A.VP of Clinical OperationsN/DN/DN/D
Mr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationN/DN/DN/D
Dr. Ana Tari Ashizawa Ph.D., MBASenior Vice President of Research, Development & Clinical DesignN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Governance aziendale

L'ISS Governance QualityScore di Bio-Path Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.